News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,644 Results
Type
Article (40083)
Company Profile (271)
Press Release (661290)
Multimedia
Podcasts (52)
Webinars (12)
Section
Business (205107)
Career Advice (2020)
Deals (35532)
Drug Delivery (97)
Drug Development (81245)
Employer Resources (172)
FDA (16210)
Job Trends (14914)
News (346479)
Policy (32647)
Tag
Academia (2572)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49782)
ALS (88)
Alzheimer's disease (1384)
Antibody-drug conjugate (ADC) (127)
Approvals (16215)
Artificial intelligence (253)
Autoimmune disease (22)
Automation (16)
Bankruptcy (363)
Best Places to Work (11658)
BIOSECURE Act (20)
Biosimilars (106)
Biotechnology (190)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (279)
Cancer (2257)
Cardiovascular disease (173)
Career advice (1688)
Career pathing (30)
CAR-T (152)
Cell therapy (427)
Cervical cancer (19)
Clinical research (66110)
Collaboration (841)
Compensation (524)
Complete response letters (19)
COVID-19 (2605)
CRISPR (41)
C-suite (242)
Cystic fibrosis (100)
Data (2197)
Decentralized trials (2)
Denatured (20)
Depression (42)
Diabetes (271)
Diagnostics (6388)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (100)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86732)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112879)
Executive appointments (729)
FDA (17459)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (752)
Gene editing (106)
Generative AI (19)
Gene therapy (302)
GLP-1 (711)
Government (4429)
Grass and pollen (4)
Guidances (59)
Healthcare (18835)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (119)
Indications (29)
Infectious disease (2748)
Inflammatory bowel disease (140)
Inflation Reduction Act (10)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16541)
IRA (42)
Job creations (3666)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (474)
Leadership (17)
Legal (7944)
Liver cancer (75)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (66)
Medical device (13388)
Medtech (13393)
Mergers & acquisitions (19533)
Metabolic disorders (684)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (89)
Neuropsychiatric disorders (27)
Neuroscience (1919)
NextGen: Class of 2025 (6548)
Non-profit (4492)
Now hiring (39)
Obesity (362)
Opinion (208)
Ovarian cancer (75)
Pain (86)
Pancreatic cancer (84)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (57637)
Pharmaceutical (67)
Pharmacy benefit managers (18)
Phase I (20611)
Phase II (29119)
Phase III (21683)
Pipeline (1184)
Policy (141)
Postmarket research (2564)
Preclinical (8772)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5953)
Recruiting (65)
Regulatory (22338)
Reports (46)
Research institute (2327)
Resumes & cover letters (350)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (132)
Series B (84)
Service/supplier (13)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3630)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (30)
Vaccines (687)
Venture capitalists (43)
Weight loss (235)
Women's health (35)
Worklife (16)
Date
Today (174)
Last 7 days (877)
Last 30 days (2642)
Last 365 days (32937)
2025 (10641)
2024 (35330)
2023 (40179)
2022 (51290)
2021 (55836)
2020 (54157)
2019 (46641)
2018 (35126)
2017 (32227)
2016 (31634)
2015 (37712)
2014 (31456)
2013 (26501)
2012 (28772)
2011 (29426)
2010 (27526)
Location
Africa (721)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (38047)
Australia (6232)
California (6124)
Canada (2009)
China (521)
Colorado (267)
Connecticut (272)
Delaware (146)
Europe (81757)
Florida (907)
Georgia (205)
Idaho (58)
Illinois (537)
India (26)
Indiana (307)
Iowa (11)
Japan (161)
Kansas (105)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (888)
Massachusetts (4566)
Michigan (219)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (64)
New Jersey (1721)
New Mexico (28)
New York (1738)
North Carolina (965)
North Dakota (8)
Northern California (2672)
Ohio (205)
Oklahoma (14)
Oregon (35)
Pennsylvania (1373)
Puerto Rico (12)
Rhode Island (33)
South America (1099)
South Carolina (22)
South Dakota (1)
Southern California (2300)
Tennessee (101)
Texas (909)
United States (23086)
Utah (180)
Virginia (145)
Washington D.C. (62)
Washington State (554)
West Virginia (3)
Wisconsin (54)
701,644 Results for "nielsen biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nielsen BioSciences Successfully Completes Enrollment into Phase 3 Trial of CANDIN for the Treatment of Common Warts
February 26, 2025
·
3 min read
Drug Development
Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts
Nielsen BioSciences, Inc. today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN ® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
March 5, 2024
·
3 min read
Business
Vial Partners with Nielsen BioSciences, Inc. in Phase III Clinical Trial for the Treatment of Common Warts
Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to study the safety and efficacy of CANDIN® for the treatment of common warts.
June 14, 2023
·
5 min read
Business
Nielsen BioSciences, Inc. Enters into License Agreement with Maruho Co. Ltd. for the Treatment of Common Warts
Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that it has entered into a license agreement with Maruho Co., Ltd. (“Maruho”), granting Maruho exclusive rights to market CANDINⓇ in Japan for the treatment of Verruca vulgaris (common warts).
May 16, 2023
·
5 min read
Press Releases
Parse Biosciences Partners with Japanese Distributor, SCRUM Inc.
April 2, 2025
·
2 min read
Press Releases
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
April 23, 2025
·
4 min read
Press Releases
Xenetic Biosciences, Inc. Releases Virtual Investor “What This Means” Segment
April 10, 2025
·
5 min read
Press Releases
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
March 31, 2025
·
7 min read
Press Releases
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
April 25, 2025
·
4 min read
Press Releases
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
April 14, 2025
·
9 min read
1 of 70,165
Next
